Date: January 2025 PMID: Category: N/A Authors: Tanaka, S (Tanaka, Sunao), Murakami, K (Murakami, Kaoru), Sakatani, T (Sakatani, Toru), Lee, RK (Lee, Riko), Hogrefe, W (Hogrefe, Wayne), Siguencia, F (Siguencia, Fernando), Rosser, CJ (Rosser, Charles J.), Furuya, H (Furuya, Hideki) DOI: 10.3390/diagnostics15020138 Background/Objectives: Urinalysis accuracy requires reliable sample stability that is dependent on the chosen collection and storage conditions. The multiplex Onc

Date: July 9, 2025 PMID: Category: N/A Authors: Wang, J (Wang, Jing), Chen, HC (Chen, Hua-chang), Hiebert, SW (Hiebert, Scott W.), Sheng, QH (Sheng, Quanhu), Tansey, WP (Tansey, William P.), Shyr, Y (Shyr, Yu), Liu, Q (Liu, Qi) DOI: 10.1093/gigascience/giaf071 Nascent RNA sequencing tracks primary transcriptional events, making it crucial for studying the immediate regulatory changes of genes and enhancers in response to both endogenous and exogenous stimuli. NRSA is a w

Date: February 22, 2026 PMID: 41725045 Category: N/A Authors: Jonas Dohmen, Lucrezia De Santis, Bret M Stephens, Vincent Bernard, Jörg C Kalff, Lara Braun, Phillipp Leyendecker, Johannes Röttgen, Daniel Weissinger, Anirban Maitra, Paola A Guerrero, Alexander Semaan DOI: https://doi.org/10.1002/1878-0261.70222 Liquid biopsies enable noninvasive tumor profiling and longitudinal disease monitoring. Their analytical performance is strongly influenced by pre-analytical factor

Date: February 2026 PMID: PMC12794688 Category: N/A Authors: Kazutoshi Fujita, Makito Miyake, Mamoru Hashimoto, Takuto Shimizu, Jennifer Linehan, Joshua Gottlieb, Ian Pagano, Sergei Tikhonenkov, Michael Luu, Sunao Tanaka, Fernando Siguencia, Kaoru Murakami, Riko Lee, Toru Sakatani, Charles J Rosser, Hideki Furuya DOI: 10.1097/JU.0000000000004803 Purpose: Urine-based assays currently have a limited role in the management of patients with upper tract urothelial carcinoma (U

Date: January 16, 2026 PMID: PMC12821410 Category: N/A Authors: Nisha Ganesh, William M Grady, Andrew M Kaz Abstract: Colitis-associated colorectal cancer (CAC) represents a distinct subtype of colorectal malignancy that arises in the setting of chronic inflammatory bowel disease (IBD). Unlike sporadic colorectal cancer, CAC develops through inflammation-driven molecular pathways, in which epigenetic alterations play a pivotal role in tumor initiation and progression. Th

Date: January 16, 2026 PMID: PMC12809115 Category: N/A Authors: Allison C Bischoff, Kristee Brown, Emily L Lasse Opsahl, Hannah R Watkoske, Carlos E Espinoza, Jude Ogechukwu Okoye, Alberto C Olivei, Leah M Green, Ridesh Rai, Stephanie The, Wei Yan, Aaron D denDekker, Eileen S Carpenter, Jiaqi Shi, Filip Bednar, Timothy L Frankel, Yaqing Zhang, Marina Pasca di Magliano Abstract: Cancer-associated fibroblasts (CAF) are a prevalent cell population in the microenvironment of

Date: January 5, 2026 PMID: PMC12774649 Category: N/A Authors: Qi Liu, Yu Wang, Chih-Yuan Hsu, Celestine N Wanjalla, Ken S Lau, Yu Shyr DOI: 10.1093/nar/gkaf1477 Spatial omics technologies enable the simultaneous measurement of molecular features within their spatial context, providing unprecedented insights into cellular organization and tissue architecture. The advent of single-cell resolution platforms has further enhanced our ability to uncover microenvironment-depend

Date: January 2 2026 PMID: PMC12757723 Category: N/A Authors: Emily L Lasse Opsahl, Carlos E Espinoza, Alberto C Olivei, Jude Ogechukwu Okoye, Hannah Watkoske, Megan T Hoffman, Faith R Avritt, Ahmed M Elhossiny, Allison C Bischoff, Katelyn L Donahue, Mary Poggi, Padma Kadiyala, Nandini Arya, Jiaqi Shi, Kyoung Eun Lee, Yaqing Zhang, Eileen S Carpenter, Julianne M Szczepanski, Timothy L Frankel, Marina Pasca di Magliano Abstract: Pancreatic cancer is associated with a high

Date: January 2 2026 PMID: 41081599 Category: N/A Authors: Michael Rubenstein, Apurv Rege, Gretchen Hubbard, Danielle Cannady, Shreya Agarwal, Kevin Chen, Alex Estrada, Carolina Gomes-Alexandre, Jessica Hicks, Tracy Jones, Qizhi Zheng, Srinivasan Yegnasubramanian, Charles J Bieberich, Angelo M De Marzo DOI: 10.1158/1541-7786.MCR-24-1206 Prostate cancer ranges from indolent to rapidly progressive. An elevated cell proliferation index portends poor outcomes, yet the molecul

Date: December 23, 2025 PMID: PMC12860476 Category: N/A Authors: Vincent Quoc-Huy Trinh, Katherine E Ankenbauer, Sabrina M Torbit, Christopher P Taranto, Jiayue Liu, Maelle Batardiere, Bhoj Kumar, H Carlo Maurer, Frank Revetta, Zhengyi Chen, Angela R S Kruse, Audra M Judd, Celina Copeland, Jahg Wong, Olivia Ben-Levy, Brenda Jarvis, Monica Brown, Jeffrey W Brown, Koushik Das, Yuki Makino, Jeffrey M Spraggins, Ken S Lau, Parastoo Azadi, Anirban Maitra, Marcus C B Tan, Kathleen

Date: December 16, 2025 PMID: PMC12820036 Category: N/A Authors: Ruoxing Li, Peng Yang, Mauro Di Pilato, Jianjun Zhang, Christopher R Flowers, Lulu Shang 7, Ziyi Li Abstract: Mapping the entire transcriptome at single-cell resolution under its natural spatial context is essential for investigating the oncogenesis and progression of diseases. The recently emerged targeted in-situ technologies retain the spatial organization of cells at high resolution, although they remai

Date: December 5, 2025 PMID: PMC12797399 Category: N/A Authors: Sunao Tanaka, Lynne R Wilkens, Loïc Le Marchand, Gong Yang, Jian-Min Yuan, Woon-Puay Koh, Martha J Shrubsole, Michael Luu, Ian Pagano, Jane C Figueiredo, Hideki Furuya, Charles J Rosser Abstract: Background: Bladder cancer (BCa) is a lethal cancer, but early-detection offers an opportunity to improve prognosis. Our objective was to develop a urine-based multi-marker panel for BCa detection across multiple lo

Date: November 4, 2025 PMID: PMC12637499 Category: N/A Authors: Kathleen Noller, Jiaying Lai, Daniel Lesperance, Ricky S Adkins, Ahmed Elhossiny, Paola A Guerrero, Kimal I Rajapakshe, Anirban Maitra, Michelle Giglio, Anup Mahurkar, Owen White, Marina Pasca Di Magliano, Michael F Ochs, Luciane T Kagohara, Laura D Wood, Rachel Karchin, Elana J Fertig Abstract: Pancreatic ductal adenocarcinoma (PDAC) arises from heterogeneous precursor lesions, including intraductal papilla

Date: October 8, 2025 PMID: PMC12505323 Category: N/A Authors: Shuqi Wang, Ying Yuan, Suyu Liu Abstract: The US Food and Drug Administration (FDA) launched Project Optimus to shift the objective of dose selection from the maximum tolerated dose to the optimal biological dose (OBD), optimizing the benefit-risk tradeoff. One approach recommended by the FDA's guidance is to conduct randomized trials comparing multiple doses. In this paper, using the selection design framewo

Date: August 31, 2025 PMID: PMC12409783 Category: N/A Authors: Yu Wang, Haichun Yang, Ruining Deng, Yuankai Huo, Qi Liu, Yu Shyr, Shilin Zhao Abstract: 40905789 Spatial transcriptomics (ST) integrates gene expression data with the spatial organization of cells and their associated histology, offering unprecedented insights into tissue biology. While existing methods incorporate either location-based or histology-informed information, none fully synergize gene expression, hist

Date: August 20, 2025 PMID: PMC12578602 Category: N/A Authors: John R Heard, Ian Pagano, Charles Rosser, Wei Shen Tan Abstract: 40846188/ DOI: 10.1016/j.urology.2025.08.031 Objective: To evaluate the performance the Hematuria Cancer Risk Score (HCRS) in combination with the urine-based biomarker test Oncuria-Detect for the detection of bladder cancer in a cohort of patients referred for hematuria evaluation. Methods: A cohort of 365 patients undergoing microscopic and gross h

Date: August 19, 2025 PMID: 10.1007/s43441-025-00860-5 Category: N/A Authors: Xiaohan Chi, Ying Yuan, Ruitao Lin Abstract: 40830695 Background: Personalized cancer treatment using combination therapies offers substantial therapeutic benefits over single-agent treatments in most cancers. However, unmet clinical needs and increasing market competition pressure drug developers to quickly optimize combination doses and clearly demonstrate the contribution of each component when d

Date: July 10, 2025 PMID: PMC12294033 Category: N/A Authors: Sunao Tanaka, Takuto Shimizu, Ian Pagano, Wayne Hogrefe, Sherry Dunbar, Charles J Rosser, Hideki Furuya Abstract: 40722499 Background/Objectives : The clinically validated multiplex Oncuria bladder cancer (BC) assay quickly and noninvasively identifies disease risk and tracks treatment success by simultaneously profiling 10 protein biomarkers in voided urine samples. Oncuria uses paramagnetic bead-based fluorescence

Date: August 22, 2025 PMID: PMC12240483 Category: N/A Authors: Yixuan Zhao, Rachael Liu, Jianchang Lin, Ying Yuan Abstract: 40626646 One common approach for dose optimization is a two-stage design, which initially conducts dose escalation to identify the maximum tolerated dose, followed by a randomization stage where patients are assigned to two or more doses to further assess and compare their risk-benefit profiles to identify the optimal dose. A limitation of this approach

Date: July 1, 2025 PMID: PMC12217943 Category: N/A Authors: Monica E Brown, Verda E Miranda, Simone Nevills, Ruiying Hu, Prasanna K Dadi, Alan J Simmons, Yanwen Xu, Yilin Yang, Mahircan Yagan, Sadia Najam, Leesa L Sampson, Mark A Magnuson, David A Jacobson, Ken S Lau, Emily Hodges, Guoqiang Gu Abstract: 40593675 Endocrine islet β cells comprise heterogenous subtypes with different gene expression and function levels. Here we study when/how this heterogeneity is induced and ho